for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AIM ImmunoTech Inc

AIM

Latest Trade

1.44USD

Change

0.06(+4.35%)

Volume

315,240

Today's Range

1.36

 - 

1.48

52 Week Range

1.11

 - 

3.06

As of on the Nyse American LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
1.38
Open
1.44
Volume
315,240
3M AVG Volume
7.17
Today's High
1.48
Today's Low
1.36
52 Week High
3.06
52 Week Low
1.11
Shares Out (MIL)
47.85
Market Cap (MIL)
68.90
Forward P/E
-3.93
Dividend (Yield %)
--

Next Event

Q4 2022 AIM ImmunoTech Inc Earnings Release

Latest Developments

More

Aim Immunotech Inc - QTRLY Loss Per Share $0.08

Aim Immunotech Q3 Operating Loss Per Share $0.08

AIM Immunotech Provides Clinical Updates On Planned Phase 2 Study Of Ampligen In Patients With Locally Advanced Or Metastatic Late-Stage Pancreatic Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AIM ImmunoTech Inc

AIM ImmunoTech Inc. is a specialty pharmaceutical company. The Company focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is a drug which is also known as a new molecular entity that contains an active moiety. It is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen (rintatolimod), It is a drug of macromolecular RNA (ribonucleic acid) molecules, It is a sterile solution indicated for the treatment of severely debilitated patients with chronic fatigue syndrome (cfs) who have been diagnosed for longer than one year.

Industry

Biotechnology & Drugs

Contact Info

2117 SW Highway 484

OCALA, FL

34473-7949

United States

+1.352.4487797

https://aimimmuno.com/

Executive Leadership

William M. Mitchell

Independent Chairman of the Board

Thomas K. Equels

President, Chief Executive Officer, Executive Vice Chairman

Ellen M Lintal

Chief Financial Officer

Peter W. Rodino

Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Secretary

David R. Strayer

Chief Scientific and Medical Officer

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-9.680

2019

-2.620

2020

-0.450

2021(E)

-0.350
Price To Earnings (TTM)
--
Price To Sales (TTM)
542.54
Price To Book (MRQ)
1.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-27.39
Return on Equity (TTM)
-27.06

Latest News

Latest News

BRIEF-Aim Immunotech Inc Signs Material Transfer And Research Agreement With Japan's National Institute Of Infectious Diseases And Shionogi

* AIM IMMUNOTECH INC - SIGNS MATERIAL TRANSFER AND RESEARCH AGREEMENT WITH JAPAN S NATIONAL INSTITUTE OF INFECTIOUS DISEASES AND SHIONOGI

BRIEF-Aim Immunotech Entered Into Specialized Services Agreement With Utah State University

* AIM IMMUNOTECH -ENTERED INTO SPECIALIZED SERVICES AGREEMENT WITH UTAH STATE UNIVERSITY

BRIEF-Aim Immunotech Provides Update On Commercial Launch Of Ampligen In Argentina For Treatment Of Chronic Fatigue Syndrome

* AIM IMMUNOTECH - PROVIDES UPDATE ON COMMERCIAL LAUNCH OF AMPLIGEN IN ARGENTINA FOR TREATMENT OF CHRONIC FATIGUE SYNDROME

BRIEF-AIM Immunotech Files A Provisional Patent Application

* AIM IMMUNOTECH INC - FILES PROVISIONAL PATENT APPLICATION FOR USE OF AMPLIGENAS A POTENTIAL THERAPYFOR COVID-19 INDUCED CHRONIC FATIGUE Source text for Eikon: Further company coverage:

BRIEF-AIM ImmunoTech Says Co Entered Into Material Transfer & Research Agreement With The University Of Rochester

* AIM IMMUNOTECH SAYS ON JUNE 1, ENTERED INTO MATERIAL TRANSFER & RESEARCH AGREEMENT WITH THE UNIVERSITY OF ROCHESTER - SEC FILING

BRIEF-AIM Immunotech Says Co, And Shenzhen Smoore Technology Announce Agreement To Research A Potential, Easy-To-Use Treatment Approach For SARS-COV-2

* AIM IMMUNOTECH INC - CO, AND SHENZHEN SMOORE TECHNOLOGY ANNOUNCE AGREEMENT TO RESEARCH A POTENTIAL, EASY-TO-USE TREATMENT APPROACH FOR SARS-COV-2

BRIEF-Aim Immunotech Files Provisional Patent Applications For Use Of Ampligen Against Coronavirus

* AIM IMMUNOTECH FILES THREE PROVISIONAL PATENT APPLICATIONS SURROUNDING AMPLIGEN® FOR USE AGAINST THE SARS-LIKE WUHAN 2019 NOVEL CORONAVIRUS Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up